Trial Profile
Novel Immuno-epigenetic Based Platform for Patients With Peripheral T-cell Lymphoma (PTCL) and Cutaneous T-cell Lymphoma (CTCL): an International Phase Ib Study of Pembrolizumab Combined With Decitabine and/or Pralatrexate
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 08 Jan 2023
Price :
$35
*
At a glance
- Drugs Decitabine (Primary) ; Pembrolizumab (Primary) ; Pralatrexate (Primary)
- Indications Cutaneous T-cell lymphoma; Peripheral T-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 13 Dec 2022 Preliminary results from the Embolden trial presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 10 Feb 2022 Planned number of patients changed from 42 to 37.
- 10 Feb 2022 Status changed from not yet recruiting to recruiting.